Compare Figs Inc (FIGS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Zimmer Biomet Holdings Inc — how do they compare? Figs Inc trades at $15.17 (market cap $2.49B), while Zimmer Biomet Holdings Inc trades at $89.36 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.8× Figs Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FIGS | ZBH | |
|---|---|---|
Market Cap | $2.49B | $16.95B |
Volume | 5,964,311 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $103.98 |
52-Week Low | $6.90 | $79.58 |
Typical Hold Time | 33 Days | 89 Days |
Enterprise Value | $2.25B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.06, down 0.28% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2025 revenue reaching $631.10M and net income of $34.25M, representing a 5.42% margin. Recent earnings beats and raised 2026 guidance indicate positive momentum, though valuation ratios remain elevated with a P/E of 45.39 and P/S of 4.02.
Wall Street maintains a bullish stance with 60% buy ratings and a $18.00 consensus price target, suggesting 28% upside potential. Key risks include execution challenges in international expansion and rich valuation multiples that require continued strong performance. The company's expanding customer base and international growth provide catalysts for future appreciation.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
